Tips

十一月美迪西將主辦2 場(chǎng)線上直播，同時(shí)參與5 場(chǎng)海內(nèi)外行業(yè)會(huì)議，期待與各位業(yè)內(nèi)同仁交流分享藥物研發(fā)新趨勢(shì)。

15^th World ADC San Diego 2024

Antibody-drug conjugates are an important class of therapeutics for the treatment of cancer. ADCs are coming of age with a remarkable surge in recent times, that has marked a turning point in their development. 15^th World ADC San Diego 2024 is only one week to go!

We are excited to invite you to visit us at Medicilon Booth #512. Our Science and Business teams are looking forward to meeting you.

SITC 2024

Ready to Meet Medicilon at SITC's 39^th Annual Meeting & Pre-Conference Programs (SITC2024)? 

We are happy to meet you in person to discuss how our services and capabilities can support your research and expedite your drug discovery and development activities. Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers. Medicilon has built a one-stop service platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

首屆創(chuàng)新藥研發(fā)和多維度治療前沿峰會(huì)

2024年11月9-10日，由四川大學(xué)華西醫(yī)院、中國(guó)細(xì)胞生物學(xué)學(xué)會(huì)主辦，中國(guó)免疫學(xué)會(huì)、四川大學(xué)華西醫(yī)院生物治療全國(guó)重點(diǎn)實(shí)驗(yàn)室、四川省國(guó)際醫(yī)學(xué)交流促進(jìn)會(huì)、四川大學(xué)華西醫(yī)院免疫炎癥研究院聯(lián)合主辦，蘇州盛杰、GenEros Bio Pharma、健橋海承辦的“首屆創(chuàng)新藥研發(fā)和多維度治療前沿峰會(huì)暨JAK-STAT信號(hào)通路發(fā)現(xiàn)30周年慶典”將在成都舉辦。

美迪西創(chuàng)始人&CEO陳春麟博士將分享“Efficacy and Preclinical Research on JAK3 Inhibitor JANEX-1 for Treatment of Allergic Reaction and Asthma”！

美迪西團(tuán)隊(duì)將在1號(hào)展位全程設(shè)展！

第十七屆百世化學(xué)制藥國(guó)際大會(huì)暨展覽會(huì)

2024年11月13-14日，由百世傳媒主辦，廣東醫(yī)谷、廣東省藥學(xué)會(huì)制藥工程專(zhuān)業(yè)委員會(huì)、廣東省生物醫(yī)藥創(chuàng)新技術(shù)協(xié)會(huì)、全球健康藥物研發(fā)中心、聊城大學(xué)生物制藥研究院等聯(lián)合主辦的“CIS-Asia 2024 第十七屆百世化學(xué)制藥國(guó)際大會(huì)暨展覽會(huì)”將在廣州舉辦。

美迪西化學(xué)部研發(fā)副總裁李志剛博士將分享“以靶向EGFR的PROTAC藥物研發(fā)為例的X-TAC研發(fā)思考”！

美迪西團(tuán)隊(duì)將在25號(hào)展位全程設(shè)展！

ACT 2024

American College of Toxicology (ACT) 2024 kicks off on November 17 2024 at JW Marriott Austin, Austin, Texas. Maybe we can work together and Medicilon can be a great partner! Come and chat with our American team at booth #117! Medicilon offers comprehensive toxicology study services designed to assess the safety profile and potential risks of pharmaceutical compounds. Our expert team collaborates closely with clients to tailor studies according to regulatory requirements and project-specific needs. Our state-of-the-art facilities, advanced platform, experienced scientists, and commitment to quality ensure that clients receive high quality, reliable, and regulatory-compliant GLP toxicology data to support the development of safe and effective pharmaceutical products. Medicilon has been at the forefront of pharmaceutical R&D for over 20 years. We have supported more than 2,000 global clients and have contributed to the IND approval of more than 490 drugs.

marketing@medicilon.com.cn
媒體與會(huì)務(wù)請(qǐng)聯(lián)系
美迪西市場(chǎng)部微信或郵箱